

1 **TITLE:**

2 **Vitamin C and E supplementation hampers cellular adaptation to endurance training in**
3 **humans: a double-blind randomized controlled trial**

4

5 Gøran Paulsen^{1,2}, Kristoffer T. Cumming¹, Geir Holden¹, Jostein Hallén¹, Bent Ronny

6 Rønnestad³, Ole Sveen⁴, Arne Skaug⁴, Ingvild Paur⁵, Nasser E. Bastani⁵, Hege Nymo

7 Østgaard¹, Charlotte Buer¹, Magnus Midttun¹, Fredrik Freuchen¹, Håvard Wiig¹, Elisabeth

8 Tallaksen Ulseth⁶, Ina Garthe², Rune Blomhoff^{5,7}, Haakon B. Benestad⁶ and Truls Raastad¹

9

10 **Affiliations:**

11 1. Norwegian School of Sport Sciences, Oslo, Norway

12 2. Norwegian Olympic Federation, Oslo, Norway

13 3. Lillehammer University College, Lillehammer, Norway

14 4. Østfold University College, Halden, Norway

15 5. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo,
16 Norway

17 6. Department of Physiology, Institute of Basic Medical Sciences, University of Oslo,
18 Oslo, Norway

19 7. Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital,
20 Oslo

21

22 **Running title:**

23 Vitamin C and E and training adaptations

24

25 **Keywords**

26 Skeletal muscle, antioxidants, Cytochrome c oxidase 4 (COX4), PGC1alpha, VO_{2max}

27

28 **Paper details**

29 Total number of words (excluding References and Figure legends): 6452

30 Number of Figures: 8

31 Number of Tables: 5

32

33 **Corresponding author**

34 Gøran Paulsen

35 Norwegian School of Sport Sciences

36 PB: 4014 Ullevål stadion, 0806 Oslo, Norway

37 Phone: 004793429420

38 E-mail: goran.paulsen@olympiatoppen.no

39

40

41 **KEY POINTS SUMMARY**

- 42 • Recent studies have indicated that antioxidant supplementation may blunt adaptations to
43 exercise, e.g., mitochondrial biogenesis induced by endurance training. Studies on
44 humans are, however, sparse and results are conflicting.
- 45 • Isolated vitamin C and E supplements are widely used, and unravelling the interference
46 of these vitamins in cellular and physiological adaptations to exercise is of interest to
47 those who exercise for health purposes and to athletes.
- 48 • Our results show that vitamin C and E supplements blunted the endurance training-
49 induced increase of mitochondrial proteins (COX4), which is needed for improving
50 muscular endurance.
- 51 • The training-induced increases in $\text{VO}_{2\text{max}}$ and running performance were not detectably
52 affected by the supplementation.
- 53 • The present study contributes to the understanding of how antioxidants interfere with
54 adaptations to exercise in humans, and the results indicate that high dosages of vitamin C
55 and E should be used with caution.

56 *Word count: 141*

57 **ABSTRACT**

58 In this double-blind, randomized, controlled trial we investigated the effects of vitamin C and
59 E supplementation on endurance training adaptations in humans.

60

61 Fifty-four young men and women were randomly allocated to receive either 1000 mg vitamin
62 C and 235 mg vitamin E daily or a placebo for 11 weeks. During supplementation, the
63 participants completed an endurance training programme consisting of 3-4 sessions per week
64 (primarily running), divided into high intensity interval sessions (4-6x4-6 minutes; >90% of
65 maximal heart rate (HR_{max})) and steady state continuous sessions (30-60 minutes; 70-90% of
66 HR_{max}). Maximal oxygen uptake (VO_{2max}), submaximal running, and a 20 m shuttle run test
67 were assessed and blood samples and muscle biopsies were collected, before and after the
68 intervention.

69

70 The vitamin C and E group increased their VO_{2max} ($8\pm 5\%$) and performance in the 20 m
71 shuttle test ($10\pm 11\%$) to the same degree as the placebo group ($8\pm 5\%$ and $14\pm 17\%$,
72 respectively). However, the mitochondrial marker cytochrome c oxidase subunit IV (COX4;
73 $+59\pm 97\%$) and cytosolic peroxisome proliferator-activated receptor-gamma coactivator 1
74 alpha (PGC-1alpha; $+19\pm 51\%$) increased in m. vastus lateralis in the placebo group, but not in
75 the vitamin C and E group (COX4: $-13\pm 54\%$, PGC-1alpha: $-13\pm 29\%$; $p\leq 0.03$, between
76 groups). Furthermore, mRNA levels of CDC42 and mitogen-activated protein kinase 1
77 (MAPK1) in the trained muscle were lower in the vitamin C and E group ($p\leq 0.05$, compared
78 to the placebo group).

79

80 Daily vitamin C and E supplementation attenuated increases in markers of mitochondrial
81 biogenesis following endurance training. However, no clear interactions were detected for

82 improvements in VO_{2max} and running performance. Consequently, vitamin C and E
83 supplementation hampered cellular adaptations in the exercised muscles, and although this was
84 not translated to the performance tests applied in this study, we advocate caution when
85 considering antioxidant supplementation combined with endurance exercise.

86 **INTRODUCTION**

87 **Paragraph 1:** Aerobic endurance exercise is highly recommended by health authorities for its
88 health rewarding effects (Garber *et al.*, 2011), and in many sports, a high muscular aerobic
89 energy capacity and VO_{2max} are prerequisites for elite performance (Saltin & Astrand, 1967).
90 Strategies for obtaining optimal endurance training effects include not only certain training
91 methods – e.g. interval training (Gibala, 2007), but also nutritional measures (Hawley *et al.*,
92 2011). Supplements containing antioxidants and vitamins are widely used for the purpose of
93 improving health and athletic achievements (Petroczi *et al.*, 2007; Kennedy *et al.*, 2013).
94 Isolated vitamin C and E supplements are among the most commonly used, despite tentative
95 evidence for the purported effects of these vitamins on health, sport performance and recovery
96 from muscle damage (Padayatty *et al.*, 2003; Nikolaidis *et al.*, 2012).

97

98 **Paragraph 2:** Contrary to common beliefs, studies have recently demonstrated that
99 antioxidant supplementation may interfere with exercise-induced cell-signalling in skeletal
100 muscle fibres (Ristow & Zarse, 2010; Hawley *et al.*, 2011). In turn, such changes in cell-
101 signalling could potentially blunt or block adaptations to training (Peternelj & Coombes,
102 2011; Gliemann *et al.*, 2013; Morales-Alamo & Calbet, 2013). For example, Gomez-Cabrera *et*
103 *al.* (2008) investigated whether high dosages of vitamin C affected adaptation to endurance
104 exercise training in both an animal and a human model (1000 mg/d in the human study; male
105 participants). Interestingly, endurance performance increased to a greater extent in animals
106 treated with the placebo compared with animals treated with vitamin C. Furthermore, markers
107 for mitochondrial biogenesis (i.e., peroxisome proliferator-activated receptor gamma co-
108 activator 1 alpha (PGC-1alpha)) increased only in animals treated with the placebo. In the
109 human experiment, changes in VO_{2max} were not significantly different between the
110 supplement and placebo groups. Unfortunately, these authors did not test endurance capacity

111 or collect muscle biopsies from the participants to verify the results of the animal study. In
112 another study with untrained and trained male participants, Ristow et al (2009) demonstrated
113 that four weeks of vitamin C (1000 mg/d) and E (400 IU/d) supplementation blunted training-
114 induced increases in the mRNA expression of genes associated with mitochondrial biogenesis
115 and endogenous antioxidant systems in skeletal muscle (e.g., PGC-1alpha and glutathione
116 peroxidase). Furthermore, Braakhuis et al (2013) observed that supplementation with 1000 mg
117 per day of vitamin C for three weeks slowed female runners during training, although no
118 differences were found in a 5 km time trial or in an incremental treadmill test after the
119 intervention period.

120

121 **Paragraph 3:** Contrary to these studies, Yfanti et al (2010;2011;2012) found no negative
122 effects of vitamin C (500 mg/d) and E (400 IU/d) supplementation in male participants who
123 trained five times a week for 12 weeks on a cycle ergometer. The antioxidant supplementation
124 did not influence changes in VO_{2max} and maximal power output (cycling), or activity of the
125 enzymes citrate synthase (CS) and beta-hydroxyacyl-CoA dehydrogenase (HAD) in skeletal
126 muscle. Similarly, Roberts et al (2011) reported no effects of vitamin C (1000 mg/d)
127 supplementation on adaptations to high-intensity running training in male participants.
128 VO_{2max} and endurance performance (10 km time trial and YoYo tests) improved equally in
129 supplemented and placebo groups. The conflicting results from these human studies are
130 reflected in recent animal studies (Gomez-Cabrera *et al.*, 2012; Nikolaidis *et al.*,
131 2012; Braakhuis, 2012).

132

133 **Paragraph 4:** Accordingly, it seems clear that antioxidant supplementation potentially
134 inhibits favourable cellular responses to endurance training. On the other hand, the
135 discrepancy between studies invites further investigation. Therefore, we studied the influence

136 of vitamin C and E supplementation on adaptations to aerobic endurance training,
137 hypothesising that high dosages of vitamin C and E, ingested shortly before and after
138 exercise, would blunt physiological adaptations to 11 weeks of endurance training. The
139 hypothesis was tested in a study with a double-blind, randomized, controlled trial design, in
140 which both training and nutrition were tightly controlled. We combined performance tests
141 with physiological measurements ($\text{VO}_{2\text{max}}$) and biochemical/molecular analyses of blood and
142 muscle.
143

144 **METHODS**

145 **Participants**

146 **Paragraph 5:** Fifty-four young, healthy men and women participated in the experiment
147 (Table 1 and Figure 1). Forty of the volunteers were defined as recreationally endurance-
148 trained individuals, because they had been endurance training 1-4 times per week for 6
149 months prior to the study. The endurance training was mainly running and cycling. Fourteen
150 volunteers were defined as untrained, because they had not trained regularly (≥ 1 session per
151 week) during the previous 6 months. Sixty-eight volunteers were recruited to the study, but 14
152 participants (7 from each group) dropped out of the study during the training intervention.
153 Five participants were injured during training (ankle sprains, and achilles pains), while nine
154 dropped out for reasons unrelated to the study.

155

156 **Paragraph 6:** The volunteers were instructed not to take any form of supplements or
157 medication (except contraceptives). Individuals who did use multi-vitamin supplements, etc.,
158 were asked to stop taking them at least two weeks before the beginning of the study.

159

160 **Paragraph 7:** The study was approved by the Regional Ethics Committee for Medical and
161 Health Research of South-East Norway and performed in accordance with the Helsinki
162 Declaration. All participants signed a written consent form.

163

164 **Experimental design**

165 **Paragraph 8:** After pre-tests and assessments (e.g., VO_{2max} and muscle biopsies), the
166 participants were randomly allocated to a vitamin C and E supplemented group or a placebo
167 group. The randomization was stratified by gender and VO_{2max} . All participants started to take
168 supplements or placebo as they started on the endurance training programme. All tests were

169 replicated after 11 weeks of training. The experiment was a double-blind, randomized,
170 controlled trial.

171

172 **Paragraph 9:** Blood samples and muscle biopsies collected before the intervention period
173 were preceded with three days of rest, and scheduled again three days after the last exercise
174 session. However, due to practical reasons, a few participants provided samples two and four
175 days after the last exercise session. There was no group bias in the sampling time points.

176

177 **Supplementation and nutrition**

178 **Paragraph 10:** The C and E vitamin and placebo pills were produced under Good
179 Manufacturing Practice (GMP) requirements at Petefa AB (Västra Frölunda, Sweden). Each
180 vitamin pill contained 250 mg of ascorbic acid and 58.5 mg DL-alpha-tocopherol acetate. The
181 placebo pills had the same shape and appearance as the vitamin pills.

182

183 **Paragraph 11:** The pills were analysed by a commercial company, Vitas (Oslo, Norway), two
184 years after production, with no sign of degradation of the vitamins (per pill: vitamin C: 255 ± 7
185 mg, vitamin E: 62 ± 2 mg). The experiments were conducted within this time period. No traces
186 of the vitamins were found in the placebo pills.

187

188 **Paragraph 12:** The participants consumed two pills (500 mg of vitamin C and 117 mg
189 vitamin E) 1-3 hours before every training session and two pills in the hour after training. On
190 non-training days the participants ingested two pills in the morning and two pills in the
191 evening. Thus, the daily dosage was 1000 mg of vitamin C and 235 mg vitamin E. The
192 supplement intake was confirmed in a training diary.

193

194 **Paragraph 13:** The participants were asked to drink no more than two glasses of juice and
195 four cups of coffee or tea per day. Juices especially rich in antioxidants, such as grape juice,
196 were to be avoided.

197

198 **Paragraph 14:** We aimed to keep the participants in energy balance, and encouraged the
199 participants to continue their normal diets. The participants completed a weighed food
200 registration dietary assessment over four days (Black *et al.*, 1991) at the start and end of the
201 intervention period. The participants used a digital food weighing scale (Vera 67002;
202 Soehnle-Waagen GmbH & Co, Murrhardt, Germany; precision 1 g). The dietary registrations
203 were analysed with a nutrient analysis programme (Mat på data 4.1; LKH, Oslo, Norway).

204

205 **Body composition**

206 **Paragraph 15:** Inbody 720 (a bioimpedance apparatus) was used to assess body composition
207 before and after the training intervention (Biospace Co., Ltd., Seoul, Korea). The apparatus
208 has been validated (compared with Dual-energy X-ray absorptiometry, DXA) for estimating
209 fat mass and lean mass in men and women (Anderson *et al.*, 2012).

210

211 **Endurance training**

212 **Paragraph 16:** The training programme was divided into three periods (Table 2). In period 1
213 the participants exercised three times per week, two continuous sessions (30 and 60 min) and
214 one interval session (4x4 min). In period 2 one extra interval session was added (4 sessions
215 per week). In periods 2 and 3 the number of runs per interval session was increased, while the
216 exercise intensity was similar throughout the training period. The exception was that the less
217 experienced runners (untrained participants) used 3-6 sessions to gradually increase the
218 intensity. The intensity was high in every session, except during the 60 min run (moderate

219 intensity). Running was the main exercise form, but one running session per week could be
220 substituted by cycling, cross-country skiing or similar whole body activity.

221

222 **Paragraph 17:** Training intensity was controlled using the Borgs scale (rating of perceived
223 exertion) and heart rate monitors (Polar RS400/RS800CX, Kempele, Finland). The heart rate
224 monitor was worn in every session and the training data were collected and controlled by the
225 investigators. Moreover, each participant was instructed to fill out a training diary, in which
226 they logged mean heart rate, running distance and perceived effort (not reported).

227

228 **VO_{2max} and submaximal workloads**

229 **Paragraph 18:** All participants underwent a familiarization session for VO_{2max} measurements
230 (mixing chamber; Jaeger Oxycon Pro, Hoechberg, Germany) on a treadmill (Woodway ELG
231 90/200 Sport, Weil am Rhein, Germany). The pre-test for VO_{2max} started with 7 minutes at
232 two submaximal running speeds (5.3% inclination), corresponding to 60 and 85% of the
233 VO_{2peak} reached during the familiarization session. VO₂, respiratory exchange ratio (RER),
234 heart rate (Polar RS400, Kempele, Finland) and rating of perceived exertion (Borgs scale)
235 were measured during the last 2 minutes at each velocity. Capillary blood from a finger-stick
236 was sampled within 1 minute after each workload and blood lactate concentration was
237 measured (YSI 1500 Sport Lactate Analyzer, YSI INC, Yellow Springs, Ohio, USA). The
238 same submaximal running velocities were used for both the pre- and post-tests.

239

240 **Paragraph 19:** After a 10 minute rest, the participants performed the VO_{2max} test. The
241 running velocity (5.3 % inclination) was increased by 1 km/h in three 1 minute stages, before
242 0.5 km/h increases per minute until exhaustion (total duration: 4-8 minutes). Lactate was
243 measured as detailed above.

244

245 **20 m shuttle run test (Beep test)**

246 **Paragraph 20:** The 20 m shuttle run test is a multistage shuttle run test that measures aerobic
247 fitness; the test has shown good reliability (Leger *et al.*, 1988). The participants ran a distance
248 of 20 m between two lines and placed one foot on the line each time a beep sounded (from a
249 CD player); the interval between beeps decreased over time. The test had 21 levels and started
250 at a speed of 8 km/h and increased with 0.5 km/h per minute. The participants ran until
251 exhaustion, which was defined as not completing the distance within the time-limit after one
252 warning. The untrained participants completed a familiarization session before this test.

253

254 **Muscle tissue sampling and pre-analytic handling**

255 **Paragraph 21:** Muscle biopsies from the mid-portion of the right m. vastus lateralis were
256 collected before and after the training intervention. The post-training insertion was located
257 proximally to the pre-training site (approximately 3 cm). The procedure was conducted under
258 local anaesthesia (Xylocain adrenalin, 10 mg/ml + 5 µg/ml, AstraZeneca, UK).
259 Approximately 200 mg (2-3 x 50-150 mg) of muscle tissue was obtained with a modified
260 Bergström-technique. Tissue intended for homogenization and protein measurements was
261 quickly washed in physiological saline, and fat, connective tissue, and blood were removed
262 before the sample was weighed and quickly frozen in isopentane cooled on dry ice. Tissue
263 intended for mRNA analyses was placed in RNAlater (Ambion, Life Technologies, Carlsbad,
264 CA). Samples for immunohistochemistry were mounted in Tissue-Tek (Cat#4583, Sakura
265 Finetek, CA, USA) and quickly frozen in isopentane cooled on liquid nitrogen. All muscle
266 samples were stored at -80 °C for later analyses.

267

268 *Protein immunoblot*

269 **Paragraph 22:** About 50 mg of muscle tissue was homogenized and fractionated into cytosol,
270 membrane, nuclear, and cytoskeletal fractions, using a commercial fractionation kit according
271 to the manufacturer's procedures (ProteoExtract Subcellular Proteo Extraction Kit,
272 Cat#539790, Calbiochem, EMD Biosciences, Germany). Protein concentrations were
273 assessed with a commercial kit (BioRad DC protein micro plate assay, Cat#0113, Cat#0114,
274 Cat#0115, Bio-Rad, CA, USA), a filter photometer (Expert 96, ASYS Hitech, UK), and the
275 provided software (Kim, ver. 5.45.0.1, Daniel Kittrich).

276

277 **Paragraph 23:** Cytosol, membrane, and nuclear fractions were analysed by the western
278 blotting technique. Equal amounts of protein were loaded per well (9-30 µg) and separated on
279 4-12% SDS-PAGE gels under denaturized conditions for 35-45 min at 200 volts in cold MES
280 running buffer (NuPAGE MES SDS running buffer, Invitrogen, CA, USA). Proteins were
281 thereafter transferred onto a PDVF-membrane (Immuno-blot, Cat#162-0177, Bio-Rad, CA,
282 USA), at 30 volts for 90 min in cold transfer buffer (NuPAGE transfer buffer, Cat#NP0006-1,
283 Life Technologies, CA, USA). Membranes were blocked at room temperature for 2 hours in a
284 5% fat free skimmed milk and 0.05% TBS-T solution (TBS, Cat#170-6435, Bio-Rad, CA,
285 USA; Tween 20, Cat#437082Q, VWR International, PA, USA; Skim milk, Cat#1.15363,
286 Merck, Germany). Blocked membranes were incubated with antibodies against HSP60
287 (mouse-anti HSP60, Cat#ADI-SPA-807, Enzo Life Sciences, NY USA; diluted 1:4000),
288 HSP70 (mouse-anti HSP70, Cat#ADI-SPA-810, Enzo Life Sciences, NY USA; diluted
289 1:4000), and COX 4 (mouse-anti-COX4, Cat#Ab14744, Abcam, Cambridge, UK; diluted
290 1:1000) overnight at 4 °C, followed by incubation with secondary antibody (goat anti-mouse,
291 Cat#31430, Thermo Scientific, IL, USA; diluted 1:30000) at room temperature for 1 hour. All
292 antibodies were diluted in a 1% fat free skimmed milk and 0.05% TBS-T solution.

293 Membranes with the PGC-1alpha molecular weight were blocked at room temperature for 2
294 hours in a 1% BSA solution (BSA 10% in PBS; deionized H₂O; Cat#37525, Thermo
295 Scientific, IL USA). Blocked membranes were incubated with primary antibodies against
296 PGC-1alpha (rabbit-anti-PGC-1alpha, C-Terminal (777-7979), Cat#516557, Calbiochem,
297 MA, USA; diluted 1:2000) overnight at 4 °C, followed by incubation with secondary antibody
298 (goat anti-rabbit IgG, Cat#7074, Cell Signaling Technology, MA, USA; diluted 1:1000) at
299 room temperature for 1 hour. Both primary and secondary antibodies were diluted in 1% BSA
300 and deionized H₂O solution. Between stages, membranes were washed in 0.05% TBS-T
301 solution. Bands were visualized using an HRP-detection system (Super Signal West Dura
302 Extended Duration Substrate, Cat#34076, Thermo Scientific, IL, USA). Chemiluminescence
303 was measured using a CCD image sensor (Image Station 2000R or Image Station 4000R,
304 Kodak, NY, USA), and band intensities were calculated with the Carestream molecular
305 imaging software (Carestream Health, NY, USA). All samples were run as duplicates and
306 mean values were used for statistical analyses.

307

308 *Immunohistochemistry*

309 **Paragraph 24:** Cross sections 8 µm thick were cut using a microtome at -20 °C (CM3050,
310 Leica, Germany) and mounted on microscope slides (Superfrost Plus, Thermo Scientific, MA,
311 USA). The sections were then air-dried and stored at -80 °C. The muscle sections were
312 blocked for 30 min with 1% BSA (bovine serum albumin; Cat#A4503, Sigma Life Science,
313 MO, USA) and 0.05% PBS-T solution (Cat#524650, Calbiochem, EMD Biosciences, CA,
314 USA). They were then incubated with antibodies against myosin heavy chain type 2 (1:1000;
315 SC71, gift from Prof. S. Schiaffino), CD31 (capillaries; 1:200; Dako, clone JC70A, M0823)
316 and dystrophin (1:1000; Cat#ab15277, Abcam, Cambridge, UK) overnight at 4°C followed by
317 incubation with appropriate secondary antibodies (Alexa Fluor, Cat#A11005 or Cat#A11001,

318 Invitrogen, CA, USA). Between stages the sections were washed 3x5 min in 0.05% PBS-T
319 solution. Muscle sections were finally covered with a coverslip and glued with ProLong Gold
320 Antifade Reagent with DAPI (Cat#P36935, Invitrogen Molecular Probes, OR, USA) and left
321 to dry overnight at room temperature. Muscle sections were visualized using a high resolution
322 camera (DP72, Olympus, Japan) mounted on a microscope (BX61, Olympus, Japan) with a
323 fluorescence light source (X-Cite 120PCQ, EXFO, Canada). Fibre type distribution, fibre
324 cross-sectional area, and capillaries were identified by TEMA software (CheckVision,
325 Hadsund, Denmark). All staining counts were manually approved/corrected independently by
326 two investigators. Capillarisation was expressed as capillaries around each fibre (CAF) and
327 CAF related to fibre area (CAFA), for type 1 and type 2 (2a and 2x) fibres.

328

329 *Gene expression analyses*

330 **Paragraph 25:** Total RNA was isolated using a “RNeasy Fibrous Tissue Mini Kit” (Qiagen,
331 CA, USA, Cat#74704) according to the manufacturer`s instructions. RNA quantity and
332 quality were determined using a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific,
333 Wilmington, DE, USA) and Agilent Bioanalyser combined with “Agilent RNA 6000 Nano
334 Kit” (Agilent Technologies, Palo Alto, CA, USA). A “High-Capacity cDNA reverse
335 transcription kit” (Applied Biosystems, Foster City, CA, USA, Cat# 4368814) was used for
336 cDNA synthesis. Q-RT-PCR was performed in a 7900HT Fast Real-Time PCR System
337 (Applied Biosystems) using 140 ng cDNA in a custom-made Taq-Man Low Density Array
338 (Applied Biosystems). Primers for the following genes were included in the array
339 (abbreviated name; Applied Biosystems Assay ID): CRYAB (Hs00157107_m1), CAT
340 (Hs00156308_m1), CDC42 (Hs00741586_mH), CS (Hs00830726_sH), COL4A1
341 (Hs01007469_m1), COX4I1 (Hs00971639_m1), CYCS (Hs01588973_m1), ESRRB
342 (Hs00607062_gH), FOXO1 (Hs01054576_m1), SLC2A4 (Hs00168966_m1), GPX1

343 (Hs00829989_gH), HIF1A (Hs00936368_m1), HMOX1 (Hs00157965_m1), HSPB2
344 (Hs00155436_m1), HSPD1 (Hs01036747_m1), HSPA1A:HSPA1B (Hs00359147_s1), HSF1
345 (Hs00232134_m1), IGF2 (Hs00171254_m1), IL6 (Hs99999032_m1), LAMA4
346 (Hs00158588_m1), MAPK1 (Hs01046830_m1), MAPK3 (Hs00385075_m1), NFKB1
347 (Hs00231653_m1), NFKB2 (Hs00174517_m1), NID2 (Hs00201233_m1), NOX1
348 (Hs00246589_m1), CYBB (Hs00166163_m1), NOX3 (Hs00210462_m1), NOX4
349 (Hs01558199_m1), NOX5 (Hs00225846_m1), NQO1 (Hs00168547_m1), NFE2L1
350 (Hs00231457_m1), NFE2L2 (Hs00232352_m1), NRF1 (Hs00602161_m1), PPARGC1B
351 (Hs00991676_m1), PPARGC1A (Hs01016724_m1), PPARA (Hs00947539_m1), PPARG
352 (Hs01115512_m1), RELA (Hs00153294_m1), SOD1 (Hs00916176_m1), SOD2
353 (Hs00167309_m1), TXN (Hs00828652_m1), VEGFA (Hs00900055_m1). Endogenous
354 controls included in the assay were: 18S, GAPDH (Hs99999905_m1), GUSB
355 (Hs99999908_m1), HPRT1 (Hs99999909_m1), TBP (Hs99999910_m1). RQ Manager
356 version 1.2 (Applied Biosystems) and Microsoft Excel 2010 were used for the data analysis.
357 The expression levels were quantified using the cycle threshold (Ct) normalized against the
358 average of the endogenous controls GUSB and HPRT1. Δ Ct represents the Ct value of the
359 target gene minus (average) Ct value of the endogenous control, and is used to calculate 2-
360 Δ Ct. A target gene was determined as “not expressed” when the average Ct was \geq 35.

361

362 **Blood sampling and handling**

363 **Paragraph 26:** Venous blood was collected in the morning after 12 hours of fasting. Heparin
364 and EDTA coated tubes were immediately centrifuged at 1500 g for 10 min at 4°C. Care was
365 taken to keep the collected plasma cooled (on ice) between steps, and to freeze the treated
366 samples rapidly in dry ice. Heparin plasma destined for vitamin C analysis was immediately
367 mixed in equal volumes with metaphosphoric acid before freezing; the further analysis

368 procedure is described by Karlsen et al (2005). Vitamin E was analysed in EDTA plasma, as
369 described by Bastani et al (2012). Plasma (heparin) 8-iso PGF 2a analyses have previously
370 been described by Bastani et al (2009). All samples were stored at -80°C until analysis.

371

372 **Statistics**

373 **Paragraph 27:** The numbers of participants included in the different tests and analyses are
374 given in Figure 1. All data were tested for Gaussian distribution with the D'Agostino &
375 Pearson omnibus normality test. A two-way ANOVA was used to evaluate the effect of
376 training (time) and vitamin C and E supplementation (absolute values, pre and post). A Holm-
377 Sidak multiple comparisons test was applied for post hoc analyses. Between groups
378 differences in relative changes (%) from before to after the intervention period (pre-post
379 changes) were assessed with an unpaired Student's t-test or the Mann Whitney test (dependent
380 on distribution). Relative changes within each group were assessed with a paired Student's t-
381 test or Wilcoxon signed rank test (dependent on distribution). For mRNA data, Mann Whitney
382 U tests were used to compare changes between groups, and Wilcoxon signed rank tests were
383 used for within-group analyses. Data are given as mean and standard deviation (SD) in text
384 and tables. The figures display max-min values, 25th and 75th quartiles and the medians
385 (boxplot), as some of the biochemical variables were not normally distributed. Outliers were
386 defined by Tukey's rule. Effect size was calculated as the differences between the group
387 means divided by the combined SD. Graphpad Prism(R) (version 6.00, La Jolla California
388 USA, www.graphpad.com) was used for statistical analyses.

389

390 **RESULTS**

391 **Paragraph 28:** The participants reported 97±5% adherence to the supplements. A survey
392 conducted after the training period confirmed that the group affiliation was indeed concealed
393 for the participants. The vitamin C and E supplementation raised plasma levels of both
394 vitamin C (before: 81±24 µM, after: 114±30 µM; p<0.001) and vitamin E (alpha-tocopherol;
395 before: 27±7 µM, after: 35±11 µM; p=0.009; Figure 2). No changes were found in the
396 placebo group (vitamin C: before: 80.9±17.2 µM, after: 81.1±19.9 µM; p=0.70; vitamin E:
397 before 25.9±6.6 µM, after: 26.6±4.2 µM; p=0.66).

398

399 **Paragraph 29:** In contrast to the C+E vitamin group (before: 87.1±49 pg·ml⁻¹, after: 85.5±43
400 pg·ml⁻¹), 8-iso PGF 2a increased in the placebo group (before: 74±33 pg·ml⁻¹, after: 88.2±29
401 pg·ml⁻¹, p=0.03), the difference between the groups being statistically significant (p=0.03;
402 Figure 3).

403

404 **Paragraph 30:** We found no significant difference in energy intake between the C+E vitamin
405 group and placebo group (~10500±3500 kJ in both groups), or for macro- or micro-nutrients
406 (data not shown). Through their regular diet, the C+E vitamin group consumed 104±72 mg of
407 vitamin C and 11±4 mg of vitamin E per day, while the placebo group consumed 102±50 mg
408 and 11±4 mg, respectively (p>0.7 between groups).

409

410 **Paragraph 31:** The C+E vitamin group reduced body mass by 1.0±2.0% (p=0.02), due to a
411 5.3±8.6% (p=0.005) loss of fat mass, but these changes were not different from those in the
412 placebo group (Table 3). The estimated muscle mass was stable in both groups.

413

414 **Paragraph 32:** All participants performed 38-45 exercise sessions during the 11 week
415 intervention. The training diary and heart rate data showed no differences in training intensity
416 and perceived exertion between the groups (data not shown).

417

418 **Paragraph 33:** VO_{2max} improved to the same degree in both groups (C+E vitamin: 52.9 ± 7.6
419 to 57.2 ± 9.6 $ml \cdot min^{-1} \cdot kg^{-1}$, placebo: 52.9 ± 8.6 to 57.1 ± 7.4 $ml \cdot min^{-1} \cdot kg^{-1}$), as did the
420 performance in the 20 m shuttle run test (C+E vitamin: 1660 ± 570 to 1800 ± 540 meters,
421 placebo: 1670 ± 550 to 1870 ± 550 meters; Figure 4).

422

423 **Paragraph 34:** The subgroup of previously untrained participants increased their VO_{2max}
424 more than the trained participants ($12.6 \pm 6.2\%$; $p < 0.001$, untrained vs. trained), but there were
425 no differences between the untrained participants in the C+E vitamin group vs. the placebo
426 group ($p = 0.98$).

427

428 **Paragraph 35:** During submaximal velocity running, corresponding to 58 ± 7 and $80 \pm 7\%$ of
429 pre VO_{2max} , the putative training effects were slightly larger in the placebo than in the C+E
430 vitamin group, specifically for heart rate and RER values (Table 4). However the group
431 differences only reached a statistical tendency ($p = 0.08-0.09$; effect size = 0.5 for both
432 variables).

433

434 **Paragraph 36:** The COX4 protein content in membrane fractions (including the
435 mitochondrial components) of samples from m. vastus lateralis increased with training only in
436 the placebo group ($p = 0.01$). A similar trend was seen for the COX4 mRNA levels from the
437 muscle biopsies (Figure 5).

438

439 **Paragraph 37:** The PGC-1alpha mRNA levels increased during training only in the C+E
440 vitamin group (Figure 6), but no significant changes were found for PGC-1alpha protein
441 content either in the cytosol or in the nuclear fraction in either group. However, a small, but
442 significant group difference was found for the change of PGC-1alpha protein levels in the
443 cytosolic fraction ($p=0.03$).

444

445 **Paragraph 38:** The heat shock proteins 60 and 70 (HSP60 and HSP70) did not change during
446 training, either at the mRNA level (some of the data given in Figure 5) or the protein level in
447 the cytosolic and nuclear fractions (Figure 7).

448

449 **Paragraph 39:** The mRNA levels of CDC42 and MAPK1 decreased in the C+E vitamin
450 group, and the changes were statistically different from those in the placebo group ($p\leq 0.05$;
451 Figure 8).

452

453 **Paragraph 40:** With no group differences in the mRNA levels, VEGF mRNA ($p=0.018$) and
454 CRYAB mRNA (alphaB-crystallin; $p=0.018$) decreased in the placebo group (supplementary
455 table display results for all analysed genes).

456

457 **Paragraph 41:** No changes or group differences were found for fibre cross-sectional area or
458 capillarisation (Table 5). When the groups were combined, there was a trend towards an
459 increased proportion of type 2 fibres ($p=0.08$).

460

461 **DISCUSSION**

462 **Paragraph 42:** In the present study we investigated the effects of vitamin C and E
463 supplementation on adaptations to endurance exercise during an 11-week double-blind,
464 randomized, controlled trial (n=54). The main findings were that the supplementation blunted
465 the training-induced up-regulation of cytosolic PGC-1alpha and the mitochondrial COX4
466 protein in m. vastus lateralis, without altering the training-induced improvements in VO_{2max}
467 and running performance. The supplementation decreased the gene expression of the
468 signalling proteins CDC42 and MAPK1, but did not alter stress proteins or capillarisation
469

470 **Cellular effects**

471 **Paragraph 43:** Although conflicting results exist, animal models have demonstrated that high
472 dosages of antioxidant supplements can shut down specific (redox sensitive) cell signalling
473 pathways, and thereby, decrease synthesis of new muscle mitochondria and endogenous
474 antioxidant production (Kang *et al.*, 2009;Hawley *et al.*, 2011;Strobel *et al.*, 2011;Villanueva
475 & Kross, 2012;Feng *et al.*, 2013). Importantly, both health benefits and improved athletic
476 performance in response to endurance training seem dependent on such cellular adaptations
477 (Coffey & Hawley, 2007;Ristow & Zarse, 2010). With human participants, we herein provide
478 novel evidence that high dosages of vitamin C and E reduce the endurance training-induced
479 increase of COX4 (in vastus lateralis), which suggests a blunted mitochondrial biogenesis.
480 The exact mechanism behind this effect is not possible to decipher. However, as suggested by
481 Ristow et al (2009;2010), we assume that the antioxidants attenuated the generation of
482 reactive oxygen and/or nitrogen species (RONS), and thereby inhibited redox-sensitive
483 signalling and blunted the induction of genes such as PGC-1alpha (as discussed further
484 below).

485

486 **Paragraph 44:** Our observations are in conflict with findings in a recent human study by
487 Yfanti et al (2010), who reported that supplementation with vitamins C and E did not alter
488 training adaptations, as assessed by changes in citrate synthase (CS) and beta-hydroxyacyl-
489 CoA dehydrogenase (HAD) activity in m. vastus lateralis. A plausible explanation of this
490 discrepancy could be that Yfanti et al supplemented with 500 mg vitamin C per day, rather
491 than 1000 mg per day as used in the present study. Furthermore, our participants were
492 instructed to take the supplements in two doses (half dosage: 500 mg vitamin C and 117.5 mg
493 vitamin E), 1-3 hours before and within one hour after each exercise session. By contrast,
494 participants in the study by Yfanti et al consumed their vitamin supplement only at breakfast.
495 Considering the pharmacokinetics of vitamin C in plasma (which decrease within a few hours;
496 (Padayatty *et al.*, 2004)), this might have caused a different cellular response to the
497 supplementation.

498

499 **Paragraph 45:** We and others (Morton *et al.*, 2009a;Feng *et al.*, 2013) have used COX4 as a
500 marker of mitochondrial content, and COX4 and total mitochondrial contents are found to
501 correlate significantly (Larsen *et al.*, 2012). Nevertheless, as a surrogate marker for
502 mitochondrial content, we should keep in mind that the COX4 content is not directly
503 comparable with changes in enzyme activity, such as citrate synthase as measured by Yfanti
504 et al (2010).

505

506 **Paragraph 46:** Mitochondrial biogenesis seems primarily regulated by PGC-1alpha, which
507 controls the expression of both nuclear and mitochondrial gene transcription, through proteins
508 such as NFR1/2 and TFAM (Lanza & Sreekumaran, 2010). The up-stream activators of PGC-
509 1alpha comprise MAPK (p38 and ERK1/2) and AMPK (Lanza & Sreekumaran, 2010;Hawley
510 *et al.*, 2011). In our study we observed that vitamin C and E supplementation blunted any rise

511 of the muscle cytosolic PGC-1alpha levels and lowered the gene expression of CDC42 and
512 MAPK1 (ERK2). These responses are consistent with the changes that we observed for
513 COX4. By contrast, PGC-1alpha mRNA was increased only in the vitamin C and E
514 supplemented group, and the nuclear PGC-1alpha protein levels were unchanged in both
515 groups. Further complicating the issue, others have recently reported that PGC-1alpha is
516 dispensable for exercise-induced mitochondrial biogenesis in mice (Rowe *et al.*, 2012).

517

518 **Paragraph 47:** Notably, our biopsies were collected 2-4 days after the last training session,
519 meaning that they do not reflect any immediate activation, subcellular movement of proteins
520 (e.g. nuclear translocation of PGC-1alpha), or gene expression during exercise.

521

522 **Paragraph 48:** CDC42 is a member of the Rho family of small GTPases (Jaffe & Hall, 2005).
523 Among various functions, CDC42 exerts certain effects via MAPKs (Maillet *et al.*, 2009), and
524 has been shown to be ROS-sensitive (Li *et al.*, 2009). Nielsen et al (2010) reported no
525 changes in the protein levels of CDC42 in response to 12 weeks of endurance training, but a
526 decrease with cessation of training. Cessation of training is certainly strongly associated with
527 a decrease in muscular fitness, including mitochondrial capacity (Henriksson, 1992).
528 Accordingly, the lower CDC42 gene expression may reflect an adverse effect of the vitamin C
529 and E supplementation, further supporting the negative effect observed on COX4 levels, and
530 sheds light on possible mechanisms for antioxidant interactions.

531

532 **Paragraph 49:** There were no significant changes in the HSP60 and HSP70 levels (mRNA or
533 cytosolic and nucleic protein). This suggests no accumulated cellular stress during the
534 endurance training, with or without C and E vitamin supplementation (Morton *et al.*, 2009b).
535 Stable HSP levels contrast with the observations of previous studies (Liu *et al.*, 2006; Morton

536 *et al.*, 2009b). This difference may reflect the fact that our participants (from whom we
537 collected muscle biopsies) were recreationally endurance trained as they entered the study
538 (Morton *et al.*, 2009b). Similarly, the training status of the participants was probably the
539 reason for the stable capillary density conditions.

540

541 **VO_{2max} and performance**

542 **Paragraph 50:** The various cellular effects of the vitamin C and E supplementation are
543 interesting, but performance outcomes are more important for athletes. Thus, in contrast to the
544 cellular observations, the increases in VO_{2max} (~8%) and the improvements in running
545 performance (20 m shuttle run test; ~10-14%) were similar in both groups. This is in line with
546 recent human studies where increased VO_{2max} due to endurance training was unaffected by
547 vitamin C and E supplementation (Aguilo *et al.*, 2007; Yfanti *et al.*, 2010; Roberts *et al.*,
548 2011). Interestingly, Gomez-Cabrera *et al.* (2008) reported that rats that were supplemented
549 with vitamin C showed the same increases in VO_{2max} as placebo animals. However, the
550 vitamin C supplementation strongly suppressed improvements in endurance performance
551 (running to exhaustion). No group differences were detected in the present study, yet it is
552 intriguing to note that the four participants with the largest improvements in running
553 performance were all in the placebo group (effect size = 0.3 in favour of the placebo group).
554 Although speculative, this could suggest that there are considerable inter-individual
555 differences in the effects of vitamin C and E supplementation. Sub-group analyses showed,
556 however, no effect of initial training status or gender on the gain in VO_{2max} and running
557 performance during the training period (data not shown).

558

559 **Paragraph 51:** In further support of (mild) negative effects of the vitamin C and E
560 supplementation, we observed improved fat oxidation (indicated by reduced RER values) and

561 reduced heart rates at submaximal workloads in the placebo group, while no significant
562 changes were detected in the vitamin C and E group. The group differences were of moderate
563 effect size, but did not reach statistical differences ($p=0.08-0.09$). Improved fat oxidation at
564 steady state submaximal workloads could theoretically be due to both a selective up-
565 regulation of enzymes, such as beta-HAD, or a gross increase in the mitochondrial mass, or
566 both (Spina *et al.*, 1996). Unfortunately, we did not measure cellular markers for fat
567 oxidation; however, our observation of a group difference in the COX4 levels, indicating
568 increased levels of mitochondrial proteins, could be related to the RER findings.

569

570 **Paragraph 52:** Although we recruited a high number of participants, compared to similar
571 studies (Nikolaidis *et al.*, 2012), we may have been underpowered to detect small, but
572 potentially true biological effects; e.g. changes in RER-values and running performance. For
573 these variables, we had only 30-45% power to detect statistical group differences of the
574 observed 3-4%.

575

576 **C and E vitamin in plasma and changes of 8-iso PGF2a**

577 **Paragraph 53:** Plasma measurements supported the efficiency of the vitamin C and E
578 supplementation – even though the C and E vitamin levels among our young, healthy
579 participants were at the upper range of reference values at baseline (Karlsen *et al.*,
580 2005; Gomez-Cabrera *et al.*, 2008; Yfanti *et al.*, 2010; Braakhuis *et al.*, 2013).

581

582 **Paragraph 54:** 8-iso PGF2a is an established oxidative stress marker (Basu & Helmersson,
583 2005), and interestingly, the vitamin C and E supplementation inhibited an elevation of 8-iso
584 PGF2a that occurred in the placebo group. Vitamin C and E supplements (alone) have been
585 found to reduce 8-iso PGF2a levels (Basu & Helmersson, 2005), although intriguingly,

586 vitamin E has been shown to act as a pro-oxidant in certain experiments (Bowry *et al.*,
587 1992;Abudu *et al.*, 2004). Endurance training has been found to lower the 8-iso PGF2a
588 plasma concentration, especially in individuals with initially high levels (Roberts *et al.*,
589 2002;Campbell *et al.*, 2010;Arikawa *et al.*, 2013). Contrary to these training studies, we
590 observed an increase in the placebo group. This increase might be explained by the intensive,
591 high-frequency running programme for participants with normal baseline 8-iso PGF2a levels.

592

593 **Supplement considerations**

594 **Paragraph 55:** Our participants were supplemented with DL-alpha-tocopherol acetate, the
595 synthetic form of vitamin E. The bioavailability and biological action of natural (D-alpha-
596 tocopherol/RRR- alpha-tocopherol) may be different (Traber *et al.*, 1994;Burton *et al.*, 1998).
597 Thus, we must be careful when comparing our results with studies that have administered the
598 natural form of vitamin E. Concerning vitamin C, there seem to be no differences in blood
599 and tissue bioavailability of synthetic and natural or flavonoid-rich vitamin C (Carr *et al.*,
600 2013).

601

602

603 **CONCLUSION**

604 **Paragraph 56:** Vitamin C and E supplementation did not affect the endurance training-
605 induced increase in VO_{2max} and running performance (20 m shuttle test). However, at the
606 muscle cellular level, the supplementation blunted the training-induced increase in
607 mitochondrial COX4 protein content. Group differences in PGC-1 alpha (cytosolic protein
608 level), and CDC42 and MAPK1 mRNA levels provide further evidence that antioxidant
609 supplementation may have interfered with exercise-induced cell signalling in skeletal muscle.
610 Moreover, the cellular results appeared to some degree to be reflected in physiological
611 adaptations, as measured under submaximal workloads (heart rate and RER). Thus,
612 supplementation with high dosages of vitamin C and E appears to diminish some of the
613 endurance training-induced adaptations in human skeletal muscles. We suggest that high
614 dosages of isolated antioxidants should be used with caution when simultaneously engaged in
615 endurance training.

616

617 **COMPETING INTERESTS**

618 None.

619

620 **AUTHOR CONTRIBUTION**

621 All authors approved the final version for publication.

622 According to the Vancouver rules:

623 *Conception and design:* Gøran Paulsen (project leader), Truls Raastad, Jostein Hallén,

624 Haakon B Benestad, Bent Ronny Rønnestad, Ole Sveen, Arne Skaug, and Rune Blomhoff.

625 *Analysis and interpretation of data:* Gøran Paulsen, Truls Raastad, Jostein Hallén, Ole Sveen,

626 Arne Skaug, Kristoffer T. Cumming, Geir Holden, Ingvild Paur, Nasser E Bastani, Hege

627 Nymo Østgaard, Charlotte Buer, Magnus Midttun, Fredrik Freuchen, Håvard Wiig, Elisabeth

628 Tallaksen Ulseth, and Ina Garthe.

629 *Drafting the article or revising it critically for important intellectual content:* Gøran Paulsen,

630 Truls Raastad, Jostein Hallén, Haakon B Benestad, Bent Ronny Rønnestad, Rune Blomhoff,

631 Ole Sveen, Arne Skaug, Kristoffer T. Cumming, Geir Holden, Ingvild Paur, Nasser E

632 Bastani, Hege Nymo Østgaard, Charlotte Buer, Magnus Midttun, Fredrik Freuchen, Håvard

633 Wiig, Elisabeth Tallaksen Ulseth, and Ina Garthe.

634

635 **FUNDING**

636 The study was partly funded by Smartfish® As (Oslo, Norway), VitaeLab (Oslo, Norway)

637 and the Norwegian Olympic Federation.

638

639 **ACKNOWLEDGEMENT**

640 The authors thank Jonathan M. Peake for valuable comments and language corrections in the

641 manuscript.

642

643 **REFERENCES**

- 644 Abudu N, Miller JJ, Attaelmannan M, & Levinson SS (2004). Vitamins in human
645 arteriosclerosis with emphasis on vitamin C and vitamin E. *Clin Chim Acta* **339**, 11-25.
- 646 Aguilo A, Tauler P, Sureda A, Cases N, Tur J, & Pons A (2007). Antioxidant diet
647 supplementation enhances aerobic performance in amateur sportsmen. *J Sports Sci* **25**, 1203-
648 1210.
- 649 Anderson LJ, Erceg DN, & Schroeder ET (2012). Utility of multifrequency bioelectrical
650 impedance compared with dual-energy x-ray absorptiometry for assessment of total and
651 regional body composition varies between men and women. *Nutr Res* **32**, 479-485.
- 652 Arikawa AY, Thomas W, Gross M, Smith A, Phipps WR, Kurzer MS, & Schmitz KH (2013).
653 Aerobic training reduces systemic oxidative stress in young women with elevated levels of
654 F2-isoprostanes. *Contemp Clin Trials* **34**, 212-217.
- 655 Bastani NE, Gundersen TE, & Blomhoff R (2009). Determination of 8-epi PGF(2alpha)
656 concentrations as a biomarker of oxidative stress using triple-stage liquid
657 chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom* **23**, 2885-2890.
- 658 Bastani NE, Kostovski E, Sakhi AK, Karlsen A, Carlsen MH, Hjeltne N, Blomhoff R, &
659 Iversen PO (2012). Reduced antioxidant defense and increased oxidative stress in spinal cord
660 injured patients. *Arch Phys Med Rehabil* **93**, 2223-2228.
- 661 Basu S & Helmersson J (2005). Factors regulating isoprostane formation in vivo. *Antioxid*
662 *Redox Signal* **7**, 221-235.
- 663 Black AE, Goldberg GR, Jebb SA, Livingstone MB, Cole TJ, & Prentice AM (1991). Critical
664 evaluation of energy intake data using fundamental principles of energy physiology: 2.
665 Evaluating the results of published surveys. *Eur J Clin Nutr* **45**, 583-599.
- 666 Bowry VW, Ingold KU, & Stocker R (1992). Vitamin E in human low-density lipoprotein.
667 When and how this antioxidant becomes a pro-oxidant. *Biochem J* **288** (Pt 2), 341-344.
- 668 Braakhuis AJ (2012). Effect of vitamin C supplements on physical performance. *Curr Sports*
669 *Med Rep* **11**, 180-184.
- 670 Braakhuis AJ, Hopkins WG, & Lowe TE (2013). Effects of dietary antioxidants on training
671 and performance in female runners. *Eur J Sport Sci*.
- 672 Burton GW, Traber MG, Acuff RV, Walters DN, Kayden H, Hughes L, & Ingold KU (1998).
673 Human plasma and tissue alpha-tocopherol concentrations in response to supplementation
674 with deuterated natural and synthetic vitamin E. *Am J Clin Nutr* **67**, 669-684.
- 675 Campbell PT, Gross MD, Potter JD, Schmitz KH, Duggan C, McTiernan A, & Ulrich CM
676 (2010). Effect of exercise on oxidative stress: a 12-month randomized, controlled trial. *Med*
677 *Sci Sports Exerc* **42**, 1448-1453.
- 678 Carr AC, Bozonet SM, Pullar JM, Simcock JW, & Vissers MC (2013). A randomized steady-
679 state bioavailability study of synthetic versus natural (kiwifruit-derived) vitamin C. *Nutrients*
680 **5**, 3684-3695.

- 681 Coffey VG & Hawley JA (2007). The molecular bases of training adaptation. *Sports Med* **37**,
682 737-763.
- 683 Feng H, Kang C, Dickman JR, Koenig R, Awoyinka I, Zhang Y, & Ji LL (2013). Training-
684 induced mitochondrial adaptation: role of peroxisome proliferator-activated receptor gamma
685 coactivator-1alpha, nuclear factor-kappaB and beta-blockade. *Exp Physiol* **98**, 784-795.
- 686 Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, &
687 Swain DP (2011). American College of Sports Medicine position stand. Quantity and quality
688 of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and
689 neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci*
690 *Sports Exerc* **43**, 1334-1359.
- 691 Gibala MJ (2007). High-intensity interval training: a time-efficient strategy for health
692 promotion? *Curr Sports Med Rep* **6**, 211-213.
- 693 Gliemann L, Schmidt JF, Olesen J, Bienso RS, Peronard SL, Grandjean SU, Mortensen SP,
694 Nyberg M, Bangsbo J, Pilegaard H, & Hellsten Y (2013). Resveratrol blunts the positive
695 effects of exercise training on cardiovascular health in aged men. *J Physiol* **591**, 5047-5059.
- 696 Gomez-Cabrera MC, Domenech E, Romagnoli M, Arduini A, Borrás C, Pallardo FV, Sastre
697 J, & Vina J (2008). Oral administration of vitamin C decreases muscle mitochondrial
698 biogenesis and hampers training-induced adaptations in endurance performance. *Am J Clin*
699 *Nutr* **87**, 142-149.
- 700 Gomez-Cabrera MC, Ristow M, & Vina J (2012). Antioxidant supplements in exercise: worse
701 than useless? *Am J Physiol Endocrinol Metab* **302**, E476-E477.
- 702 Hawley JA, Burke LM, Phillips SM, & Spriet LL (2011). Nutritional modulation of training-
703 induced skeletal muscle adaptations. *J Appl Physiol* **110**, 834-845.
- 704 Henriksson J (1992). Effects of physical training on the metabolism of skeletal muscle.
705 *Diabetes Care* **15**, 1701-1711.
- 706 Jaffe AB & Hall A (2005). Rho GTPases: biochemistry and biology. *Annu Rev Cell Dev Biol*
707 **21**, 247-269.
- 708 Kang C, O'Moore KM, Dickman JR, & Ji LL (2009). Exercise activation of muscle
709 peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling is redox
710 sensitive. *Free Radic Biol Med* **47**, 1394-1400.
- 711 Karlsen A, Blomhoff R, & Gundersen TE (2005). High-throughput analysis of vitamin C in
712 human plasma with the use of HPLC with monolithic column and UV-detection. *J*
713 *Chromatogr B Analyt Technol Biomed Life Sci* **824**, 132-138.
- 714 Kennedy ET, Luo H, & Houser RF (2013). Dietary supplement use pattern of U.S. adult
715 population in the 2007-2008 National Health and Nutrition Examination Survey (NHANES).
716 *Ecol Food Nutr* **52**, 76-84.
- 717 Lanza IR & Sreekumaran NK (2010). Regulation of skeletal muscle mitochondrial function:
718 genes to proteins. *Acta Physiol (Oxf)* **199**, 529-547.

- 719 Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel R,
720 Helge JW, Dela F, & Hey-Mogensen M (2012). Biomarkers of mitochondrial content in
721 skeletal muscle of healthy young human subjects. *J Physiol* **590**, 3349-3360.
- 722 Leger LA, Mercier D, Gadoury C, & Lambert J (1988). The multistage 20 metre shuttle run
723 test for aerobic fitness. *J Sports Sci* **6**, 93-101.
- 724 Li QF, Spinelli AM, & Tang DD (2009). Cdc42GAP, reactive oxygen species, and the
725 vimentin network. *Am J Physiol Cell Physiol* **297**, C299-C309.
- 726 Liu Y, Gampert L, Nething K, & Steinacker JM (2006). Response and function of skeletal
727 muscle heat shock protein 70. *Front Biosci* **11**, 2802-2827.
- 728 Maillet M, Lynch JM, Sanna B, York AJ, Zheng Y, & Molkenin JD (2009). Cdc42 is an
729 antihypertrophic molecular switch in the mouse heart. *J Clin Invest* **119**, 3079-3088.
- 730 Morales-Alamo D & Calbet JA (2013). Free radicals and sprint exercise in humans. *Free*
731 *Radic Res*.
- 732 Morton JP, Croft L, Bartlett JD, MacLaren DP, Reilly T, Evans L, McArdle A, & Drust B
733 (2009a). Reduced carbohydrate availability does not modulate training-induced heat shock
734 protein adaptations but does upregulate oxidative enzyme activity in human skeletal muscle. *J*
735 *Appl Physiol* **106**, 1513-1521.
- 736 Morton JP, Kayani AC, McArdle A, & Drust B (2009b). The exercise-induced stress response
737 of skeletal muscle, with specific emphasis on humans. *Sports Med* **39**, 643-662.
- 738 Nielsen S, Scheele C, Yfanti C, Akerstrom T, Nielsen AR, Pedersen BK, & Laye MJ (2010).
739 Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle. *J*
740 *Physiol* **588**, 4029-4037.
- 741 Nikolaidis MG, Kerksick CM, Lamprecht M, & McAnulty SR (2012). Does vitamin C and E
742 supplementation impair the favorable adaptations of regular exercise? *Oxid Med Cell Longev*
743 **2012**, 707941.
- 744 Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, Chen S, Corpe C, Dutta A, Dutta
745 SK, & Levine M (2003). Vitamin C as an antioxidant: evaluation of its role in disease
746 prevention. *J Am Coll Nutr* **22**, 18-35.
- 747 Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, & Levine M
748 (2004). Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern*
749 *Med* **140**, 533-537.
- 750 Peternelj TT & Coombes JS (2011). Antioxidant supplementation during exercise training:
751 beneficial or detrimental? *Sports Med* **41**, 1043-1069.
- 752 Petroczi A, Naughton DP, Mazanov J, Holloway A, & Bingham J (2007). Performance
753 enhancement with supplements: incongruence between rationale and practice. *J Int Soc Sports*
754 *Nutr* **4**, 19.

- 755 Ristow M & Zarse K (2010). How increased oxidative stress promotes longevity and
756 metabolic health: The concept of mitochondrial hormesis (mitohormesis). *Exp Gerontol* **45**,
757 410-418.
- 758 Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehntopf M, Stumvoll M, Kahn
759 CR, & Bluher M (2009). Antioxidants prevent health-promoting effects of physical exercise
760 in humans. *Proc Natl Acad Sci U S A* **106**, 8665-8670.
- 761 Roberts CK, Vaziri ND, & Barnard RJ (2002). Effect of diet and exercise intervention on
762 blood pressure, insulin, oxidative stress, and nitric oxide availability. *Circulation* **106**, 2530-
763 2532.
- 764 Roberts LA, Beattie K, Close GL, & Morton JP (2011). Vitamin C consumption does not
765 impair training-induced improvements in exercise performance. *Int J Sports Physiol Perform*
766 **6**, 58-69.
- 767 Rowe GC, El-Khoury R, Patten IS, Rustin P, & Arany Z (2012). PGC-1alpha is dispensable
768 for exercise-induced mitochondrial biogenesis in skeletal muscle. *PLoS One* **7**, e41817.
- 769 Saltin B & Astrand PO (1967). Maximal oxygen uptake in athletes. *J Appl Physiol* **23**, 353-
770 358.
- 771 Spina RJ, Chi MM, Hopkins MG, Nemeth PM, Lowry OH, & Holloszy JO (1996).
772 Mitochondrial enzymes increase in muscle in response to 7-10 days of cycle exercise. *J Appl*
773 *Physiol* (1985) **80**, 2250-2254.
- 774 Strobel NA, Peake JM, Matsumoto A, Marsh SA, Coombes JS, & Wadley GD (2011).
775 Antioxidant supplementation reduces skeletal muscle mitochondrial biogenesis. *Med Sci*
776 *Sports Exerc* **43**, 1017-1024.
- 777 Traber MG, Ramakrishnan R, & Kayden HJ (1994). Human plasma vitamin E kinetics
778 demonstrate rapid recycling of plasma RRR-alpha-tocopherol. *Proc Natl Acad Sci U S A* **91**,
779 10005-10008.
- 780 Villanueva C & Kross RD (2012). Antioxidant-induced stress. *Int J Mol Sci* **13**, 2091-2109.
- 781 Yfanti C, Akerstrom T, Nielsen S, Nielsen AR, Mounier R, Mortensen OH, Lykkesfeldt J,
782 Rose AJ, Fischer CP, & Pedersen BK (2010). Antioxidant supplementation does not alter
783 endurance training adaptation. *Med Sci Sports Exerc* **42**, 1388-1395.
- 784 Yfanti C, Fischer CP, Nielsen S, Akerstrom T, Nielsen AR, Veskoukis AS, Kouretas D,
785 Lykkesfeldt J, Pilegaard H, & Pedersen BK (2012). Role of vitamin C and E supplementation
786 on IL-6 in response to training. *J Appl Physiol* **112**, 990-1000.
- 787 Yfanti C, Nielsen AR, Akerstrom T, Nielsen S, Rose AJ, Richter EA, Lykkesfeldt J, Fischer
788 CP, & Pedersen BK (2011). Effect of antioxidant supplementation on insulin sensitivity in
789 response to endurance exercise training. *Am J Physiol Endocrinol Metab* **300**, E761-E770.
790
791

792 **TABLES**

793 Table 1. Characteristics of the participants in the vitamin C and E group
794 and the placebo group.

	C+E-vitamin	Placebo
	N=27:	N=27:
	14 women, 13 men	14 women, 13 men
Age (years)	25±5	24±6
Height (m)	1.74±0.10	1.76±0.10
Body mass (kg)	74±14	70±12
VO_{2max} (ml·min⁻¹·kg⁻¹)	53±9	53±8

795

796

797

798

799

800

801

802

803

804

805

806 Table 2. Outline of the endurance training programme.

Weeks	Period	Day#1	Day#2	Day#3	Day#4
1-3	1	Continuous: 30 min: 82-87% of HR _{max} ; Borg: 15-17	Interval: 4x4 min: >90% of HR _{max} ; Borg: 16-18	Continuous: 45-60 min: 72-82% of HR _{max} ; Borg: 13-16	
4-8	2	Continuous: 30 min: 82-87% of HR _{max} ; Borg: 15-17(18)	Interval: 5x4 min: >90% of HR _{max} ; Borg: 16-18	Continuous: 60 min: 72-82% of HR _{max} ; Borg: 13-16	Interval: 4x6 min: >90% of HR _{max} ; Borg: 16-18
9-11	3	Continuous: 30 min: 82-87% of HR _{max} ; Borg: 15-17(18)	Interval: 6x4 min: >90% of HR _{max} ; Borg: 16-18	Continuous: 60 min: 72-82% of HR _{max} ; Borg: 13-16	Interval: 5x6 min: >90% of HR _{max} ; Borg: 16-18

807 HR_{max}: Maximal heart rate, Borg: Borg scale of perceived exertion (6-20).

808 Table 3. Body composition before and after the 11-week intervention period.

	C+E-vitamin			Placebo			<i>P-value group diff. (%-change)</i>
	<i>Pre</i>	<i>Post</i>	<i>%-change</i>	<i>Pre</i>	<i>Post</i>	<i>%-change</i>	
Body mass (kg)	73.9±14.2	73.1±13.7*	-1.0±2.0**	70.2±11.8	69.5±12.5	-1.1±2.8	0.856
Fat mass (kg)	15.5±7.1	14.6±6.8*	-5.3±8.9**	12.6±5.8	12.2±5.9	-3.3±12.1	0.497
Fat%	20.8±8.2	19.8±7.9*	-4.6±7.7**	18.1±7.1	17.6±7.2	-2.0±11.0	0.324
Muscle mass (kg)	32.9±7.2	33.0±7.1	0.4±2.2	32.4±6.6	32.3±6.8	-0.4±2.6	0.206

809 Within group changes: *: p<0.05; **: p<0.01. Exact p-values for group comparisons of

810 relative changes between groups are also displayed.

811

812

813 Table 4. Changes in oxygen uptake (VO_2), heart rate (HR), respiratory exchange rate (RER)
 814 and lactate during submaximal workloads at approximately 60% and 80% of $\text{VO}_{2\text{max}}$ at
 815 baseline.

	C+E-vitamin			Placebo			<i>P-value group diff. (%-change)</i>
<i>60 % of pre $\text{VO}_{2\text{peak}}$</i>	<i>Pre</i>	<i>Post</i>	<i>%-change</i>	<i>Pre</i>	<i>Post</i>	<i>%-change</i>	
VO_2 ($\text{ml}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$)	30.9±5.9	30.4±6.3	-1.4±8.7	30.3±4.5	29.1±5.2	-3.6±11.3	0.430
HR ($\text{beats}\cdot\text{min}^{-1}$)	140.8±13.2	136.2±12.7	-3.0±6.7	140.9±17.3	131.7±15.9	-6.3±7.2**	0.095
RER ($\text{VCO}_2:\text{VO}_2$)	0.89±0.05	0.89±0.05	0.3±5.4	0.91±0.04	0.89±0.04	-1.7±5.1	0.168
Lactate ($\text{mmol}\cdot\text{l}$)	1.6±0.9	1.3±0.5	-3.5±33.4	1.5±0.9	1.3±0.7	-6.1±32.5	0.776
<i>80 % of pre $\text{VO}_{2\text{peak}}$</i>	<i>Pre</i>	<i>Post</i>	<i>%-change</i>	<i>Pre</i>	<i>Post</i>	<i>%-change</i>	
VO_2 ($\text{ml}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$)	42.4±7.9	42.5±8.9	-0.1±6.7	41.7±5.2	41.4±6.0	-0.4±9.0	0.919
HR ($\text{beats}\cdot\text{min}^{-1}$)	170.1±11.1	165.0±13.3	-2.9±5.9	169.8±15.5	161.6±14.6	-4.7±4.4**	0.214
RER ($\text{VCO}_2:\text{VO}_2$)	0.93±0.04	0.92±0.05	-1.5±5.3	0.95±0.04	0.91±0.03	-3.9±4.5**	0.083
Lactate ($\text{mmol}\cdot\text{l}$)	3.8±2.2	2.5±1.3	-27.4±25.1**	3.3±2.2	2.4±1.3	-18±26.0**	0.270

816 Within group changes: *: $p<0.05$; **: $p<0.01$. Exact p-values for group comparisons of relative
 817 changes between groups are also displayed.

818

819

820

821

822

823

824

825

826

827

828 Table 5. Fibre type distribution, fibre area, and capillarisation.

	C+E-vitamin			Placebo			<i>P</i> -value group diff. (%-change)
	<i>Pre</i>	<i>Post</i>	%-change	<i>Pre</i>	<i>Post</i>	%-change	
Fibre type 1 (%)	54±12	51±12	-3.9±22.9	49±13	44±11	-7.4±28.5	0.124
CSA (µm²) fibre type 1	5070±1614	5202±1409	5.6±22.1	5021±1702	4893±1206	3.7±35.2	0.455
CAF fibre type 1	4.4±0.9	4.4±0.9	-0.6±13.1	4.1±0.8	4.2±0.7	1.3±13.6	0.774
CAFA fibre type 1	0.9±0.2	0.9±0.2	-1.6±26.0	0.9±0.2	0.9±0.3	7.0±35.9	0.746
CSA (µm²) fibre type 2	4831±1646	5245±2048	11.3±34.3	5845±2207	6019±2368	4.5±34.2	0.234
CAF fibre type 2	3.8±1.0	3.8±1.0	3.1±17.1	4.0±0.7	4.0±0.9	0.7±14.4	0.730
CAFA fibre type 2	0.8±0.2	0.8±0.2	0.0±30.3	0.7±0.2	0.8±0.5	10.4±57.0	0.579

829 CAF: capillaries around each fibre; CAFA: CAF/fibre area.

830 **FIGURE LEGENDS**

831 Figure 1. Outline of the numbers of trained and untrained participants in each group, and the
832 numbers of participants in tests and analyses applied.

833 Figure 2. Boxplot (max-min values, 25th-75th quartiles, and median) of percentage changes in
834 the plasma levels of vitamin C and vitamin E in the vitamin C and E group and the placebo
835 group. ●: outliers (Tukey's rule); #: difference between groups; *: within group changes.

836 Figure 3. Boxplot of percentage changes in plasma 8-iso-prostane in the vitamin C and E
837 group and the placebo group. ●: outliers (Tukey's rule); #: difference between groups; *:
838 within group changes.

839 Figure 4. Boxplot of percentage changes in VO_{2max} and the 20 m shuttle run test in the vitamin
840 C and E group and the placebo group. ●: outliers (Tukey's rule); #: difference between
841 groups; *: within group changes.

842 Figure 5. Boxplot of percentage changes in COX4 mRNA, COX4 (protein), HSP60 mRNA
843 and HSP60 (protein) in the vitamin C and E group and the placebo group. ●: outliers (Tukey's
844 rule); *: within group changes. Exact p-values denote tendencies for group differences.

845 Figure 6. Boxplot of percentage changes in PGC1alpha mRNA and PGC1alpha in cytosol and
846 nuclear fractions in the vitamin C and E group and the placebo group. ●: outliers (Tukey's
847 rule); #: difference between groups; *: within group changes.

848 Figure 7. Boxplot of percentage changes in the HSP60 and HSP70 levels in cytosol and
849 nuclear fractions in the vitamin C and E group and the placebo group. ●: outliers (Tukey's
850 rule).

851 Figure 8. Boxplot of percentage changes in CDC42 mRNA and MAPK1 mRNA in the
852 vitamin C and E group and the placebo group. ●: outliers (Tukey's rule); #: difference
853 between groups; *: within group changes.

854

Figure 1




Figure 2





Figure 3




Figure 4





Figure 5







Figure 6






Figure 7




Figure 8

